BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu J, Han M, Li J, Yang X, Yang D. Immunopathogenesis of HBV Infection. In: Tang H, editor. Hepatitis B Virus Infection. Singapore: Springer; 2020. pp. 71-107. [DOI: 10.1007/978-981-13-9151-4_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang Y, Li X, Chen Q, Jiao F, Shi C, Pei M, Wang L, Gong Z. The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients. J Med Virol 2021. [PMID: 34061368 DOI: 10.1002/jmv.27114] [Reference Citation Analysis]
2 El-mesery M, El-mowafy M, Youssef LF, El-mesery A, Abed SY, Elgaml A. Serum Soluble Fibrinogen-Like Protein 2 Represents a Novel Biomarker for Differentiation Between Acute and Chronic Egyptian Hepatitis B Virus-Infected Patients. Journal of Interferon & Cytokine Research 2021;41:52-9. [DOI: 10.1089/jir.2020.0118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Nečasová I, Stojaspal M, Motyčáková E, Brom T, Janovič T, Hofr C. Transcriptional regulators of human oncoviruses: structural and functional implications for anticancer therapy. NAR Cancer 2022;4:zcac005. [PMID: 35252867 DOI: 10.1093/narcan/zcac005] [Reference Citation Analysis]
4 Qiu H, Wang N, Lin D, Yuan Y, Li J, Mao D, Meng Y. The positive feedback loop of furin and TGFβ1 enhances the immune responses of Tregs to hepatocellular carcinoma cells and hepatitis B virus in vitro. Cell Biol Int 2022. [PMID: 35349767 DOI: 10.1002/cbin.11806] [Reference Citation Analysis]
5 Guo F, Yuan Y, Chen Z, Gao F, Li X, Wang H, Wang X, Bai G. Downregulation of the long non-coding RNA MALAT1 in tenofovir-treated pregnant women with hepatitis B virus infection promotes immune recovery of natural killer cells via the has-miR-155-5p/HIF-1α axis. International Immunopharmacology 2022;107:108701. [DOI: 10.1016/j.intimp.2022.108701] [Reference Citation Analysis]
6 Zhang Q, Yang L, Liu S, Zhang M, Jin Z. Interleukin-35 Suppresses Interleukin-9-Secreting CD4+ T Cell Activity in Patients With Hepatitis B-Related Hepatocellular Carcinoma. Front Immunol 2021;12:645835. [PMID: 34177894 DOI: 10.3389/fimmu.2021.645835] [Reference Citation Analysis]
7 Xu F, Zeng Z, Yan B, Fu Y, Sun Y, Yang G, Tu L, Watanabe S, Jabbour SK, Bravaccini S, Fanini F, Zhou J, Shen Y. Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study. Transl Lung Cancer Res 2021;10:1819-28. [PMID: 34012795 DOI: 10.21037/tlcr-21-79] [Reference Citation Analysis]
8 Li H, Xu QY, Xie Y, Luo JJ, Cao HX, Pan Q. Effects of chronic HBV infection on lipid metabolism in non-alcoholic fatty liver disease: A lipidomic analysis. Ann Hepatol. 2021;24:100316. [PMID: 33515803 DOI: 10.1016/j.aohep.2021.100316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Akbar SMF, Al Mahtab M, Aguilar JC, Yoshida O, Penton E, Gerardo GN, Hiasa Y. Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial. Pathogens 2021;10:1440. [PMID: 34832596 DOI: 10.3390/pathogens10111440] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Akbar SMF, Al Mahtab M, Khan S, Yoshida O, Aguilar JC, Gerardo GN, Hiasa Y. Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside. Vaccines 2022;10:746. [DOI: 10.3390/vaccines10050746] [Reference Citation Analysis]
11 Hu H, Shen Y, Hu M, Zheng Y, Xu K, Li L. Incidence and Influencing Factors of New Hepatitis B Infections and Spontaneous Clearance: A Large-Scale, Community-Based Study in China. Front Med (Lausanne) 2021;8:717667. [PMID: 34869415 DOI: 10.3389/fmed.2021.717667] [Reference Citation Analysis]
12 Yang Y, Ying G, Wu S, Wu F, Chen Z. In vitro inhibition effects of hepatitis B virus by dandelion and taraxasterol. Infect Agent Cancer 2020;15:44. [PMID: 32647534 DOI: 10.1186/s13027-020-00309-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]